Oxford BioDynamics Plc (LON:OBD – Get Free Report)’s stock price rose 6.8% on Thursday. The company traded as high as GBX 0.15 and last traded at GBX 0.11. 139,376,188 shares changed hands during trading, an increase of 400% from the average daily volume of 27,868,387 shares. The stock had previously closed at GBX 0.10.
Oxford BioDynamics Price Performance
The company has a debt-to-equity ratio of 131.61, a current ratio of 2.01 and a quick ratio of 2.80. The company has a market capitalization of £14.79 million, a P/E ratio of -0.55 and a beta of 0.42. The company has a 50 day moving average of GBX 0.11 and a 200-day moving average of GBX 0.17.
About Oxford BioDynamics
Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Featured Stories
- Five stocks we like better than Oxford BioDynamics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
